Novel Combinations of Agents Targeting Translation That Synergistically Inhibit Fungal Pathogens

Cindy Vallières¹, Roxane Raulo¹, Matthew Dickinson² and Simon V. Avery¹*

¹ School of Life Sciences, University of Nottingham, University Park Campus, Nottingham, United Kingdom, ² School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, United Kingdom

A range of fungicides or antifungals are currently deployed to control fungi in agriculture or medicine, but resistance to current agents is growing so new approaches and molecular targets are urgently needed. Recently, different aminoglycoside antibiotics combined with particular transport inhibitors were found to produce strong, synergistic growth-inhibition of fungi, by synergistically increasing the error rate of mRNA translation. Here, focusing on translation fidelity as a novel target for combinatorial antifungal treatment, we tested the hypothesis that alternative combinations of agents known to affect the availability of functional amino acids would synergistically inhibit growth of major fungal pathogens. We screened 172 novel combinations against three phytopathogens (Rhizoctonia solani, Zymoseptoria tritici, and Botrytis cinerea) and three human pathogens (Cryptococcus neoformans, Candida albicans, and Aspergillus fumigatus), showing that 48 combinations inhibited strongly the growth of the pathogens; the growth inhibition effect was significantly greater with the agents combined than by a simple product of their individual effects at the same doses. Of these, 23 combinations were effective against more than one pathogen, including combinations comprising food-and-drug approved compounds, e.g., quinine with bicarbonate, and quinine with hygromycin. These combinations [fractional inhibitory combination (FIC) index ≤0.5] gave up to 100% reduction of fungal growth yield at concentrations of agents which, individually, had negligible effect. No synergy was evident against bacterial, plant or mammalian cells, indicating specificity for fungi. Mode-of-action analyses for quinine + hygromycin indicated that synergistic mistranslation was the antifungal mechanism. That mechanism was not universal as bicarbonate exacerbated quinine action by increasing drug uptake. The study unveils chemical combinations and a target process with potential for control of diverse fungal pathogens, and suggests repurposing possibilities for several current therapeutics.

Keywords: antifungal combinations, amino acids, synergistic fungicides, plant pathogens, fungal disease, crop protection
INTRODUCTION

A wide range of fungi are undesirable for different reasons, including human and plant pathogens. Pathogenic fungi of humans, such as the ascomycetes Candida albicans and Aspergillus fumigatus, and the basidiomycete Cryptococcus neoformans, cause life-threatening infections particularly for individuals with compromised immunity. Invasive fungal infections have mortality rates between 20 and 95% and are estimated to cause ~1.5 million deaths annually, comparable to the mortality associated with tuberculosis and malaria (Brown et al., 2012; Calderone et al., 2014; Denning and Bromley, 2015). Compared to antibacterial treatments, the current arsenal of approved agents for the treatment of fungal infections is limited, with only four classes of antifungal compound targeting different structures or pathways. Their efficacy is eroded by toxicity or drug resistance (Vandeputte et al., 2012; Delarze and Sanglard, 2015; Van Dijck et al., 2018). The paucity of current treatments can be explained partly by the common eukaryotic nature of fungal pathogens and their hosts. Therefore, finding fungal-specific agents is challenging. In addition, a number of fungi are major plant pathogens, with the potential to devastate food crops (Cools and Hammond-Kosack, 2013; Oliver and Hewitt, 2014). Reflecting this, the global fungicide market is worth more than $7 billion annually. A wide range of fungicides have been developed and approved to counter these phytopathogens. However, the agrichemical industry also faces concerns surrounding resistance emergence combined with tightening of fungicide regulations (Oliver and Hewitt, 2014; Coste and Vandeputte, 2015), underscoring the urgent need for new effective treatments for fungal control.

Combination treatments to control fungal growth provide an attractive strategy for management. Such combinations often allow decreased effective-doses versus single agent usage, especially where the agents act synergistically, and this can lower the costs and potential for toxicity (Johnson et al., 2004; Zimmermann et al., 2007; Spitzer et al., 2017). For example, the current gold standard antifungal treatment for cryptococcal meningitis is a combination of 5-flucytosine and amphotericin B. A mixture of mancozeb and copper hydroxide, two agents with multi-site contact activity, is used in agriculture for protection to devastate food crops (Cools and Hammond-Kosack, 2013; Oliver and Hewitt, 2014). Reflecting this, the global fungicide market is worth more than $7 billion annually. A wide range of fungicides have been developed and approved to counter these phytopathogens. However, the agrichemical industry also faces concerns surrounding resistance emergence combined with tightening of fungicide regulations (Oliver and Hewitt, 2014; Coste and Vandeputte, 2015), underscoring the urgent need for new effective treatments for fungal control.

Combination treatments to control fungal growth provide an attractive strategy for management. Such combinations often allow decreased effective-doses versus single agent usage, especially where the agents act synergistically, and this can lower the costs and potential for toxicity (Johnson et al., 2004; Zimmermann et al., 2007; Spitzer et al., 2017). For example, the current gold standard antifungal treatment for cryptococcal meningitis is a combination of 5-flucytosine and amphotericin B. A mixture of mancozeb and copper hydroxide, two agents with multi-site contact activity, is used in agriculture for protection from fungal diseases. Moreover, combinatorial inhibition can slow the evolution of resistance. Another advantage of such combinations is that they may allow existing, approved drugs to be repurposed (in novel combination treatments), bypassing the costly and time-consuming development of new drugs or fungicidal agents.

Strong synergistic interactions between potential antifungals are not very common. Detection of novel synergies can be facilitated by screening approaches and/or the use of a good model system. The yeast Saccharomyces cerevisiae is widely deployed as a eukaryotic cell model, with an advanced molecular toolbox. Such advantages have been applied to characterize mechanisms of antifungal drug action and find synergistic antifungal combinations (Islahudin et al., 2013; Moreno-Martinez et al., 2015; Robbins et al., 2015). In one study, a strong, synergistic inhibition of yeast growth was noted when the aminoglycoside antibiotic paromomycin was combined with chromate (Holland et al., 2007). This example of synergy has been further considered for its antifungal potential (Moreno-Martinez et al., 2015). It was shown that paromomycin plus chromate also caused strong growth-inhibition of several human pathogens and phytopathogens. Furthermore, these agents could be substituted with alternative aminoglycosides or sulfate-transport inhibitors, respectively, to achieve synergistic inhibition (Moreno-Martinez et al., 2015). Aminoglycosides cause errors in the process of mRNA translation, i.e., mistranslation (Carter et al., 2000; Fan-Minogue and Bedwell, 2008). In the case of sulfate-transport inhibitors, it was shown that: (i) cysteine and methionine starvation could mimic Cr-induced translation errors, (ii) genetic suppression of S starvation suppressed Cr-induced mistranslation, and (iii) mistranslation required cysteine and methionine biosynthesis (Holland et al., 2010). The inferred mechanism of synergy was that sulfate limitation, caused by chromate or other sulfate mimetic, decreases the supply of S containing amino acids needed for translation, so synergizing with the ribosome-targeting aminoglycosides (Moreno-Martinez et al., 2015; Vallieres and Avery, 2017a). Therefore, these studies revealed a combination treatment that appeared to act on translation fidelity, a novel potential target for antifungal action.

In the present study, we considered a much more diverse range of compound classes with the potential to affect availability of amino acids for protein synthesis. Depletion of particular amino acids within cells can alter the competition between cognate and non-cognate aminocetyl-tRNAs, leading to mistranslation (Gallant and Lindsley, 1998; Farabaugh and Bjork, 1999; Sorensen, 2001). We hypothesized that the alternative compound classes could also target translation-fidelity synergistically when supplied in appropriate combinations. Out of the 172 novel combinations screened here, 48 were found to be effective in suppressing growth of fungal phytopathogens and/or human pathogens. Discovery of novel synergistic combinations could offer a panel of alternatives to help realize stability, toxicity, cost or resistance advantages in antifungal applications, while helping toward understanding of the molecular bases for synergistic mistranslation observed here.

MATERIALS AND METHODS

Strains, Culture, and Maintenance
Pathogenic organisms used in this study were the yeasts C. albicans SC5314 and C. neoformans 1841, the filamentous fungi A. fumigatus CBS 144.89, Botrytis cinerea SAR109940, Rhizoctonia solani AG2-1 1939 and Zymoseptoria tritici, and the bacterium Pseudomonas aeruginosa PA-W1 (kindly provided by Miguel Camara, University of Nottingham, United Kingdom). Mode of action studies were performed with S. cerevisiae BY4743 (MATα/α his3Δ1/Δ1 leu2Δ0/Δ0 lys2Δ0/Δ0 met15Δ0/Δ0 Met50) and yeast (MATα/α his3Δ1/Δ1 leu2Δ0/Δ0 lys2Δ0/Δ0 met15Δ0/Δ0 Met50) with ura3Δ0/Δ0. The yeasts were maintained and grown in YPD medium [2% peptone (Oxoid, Basingstoke, United Kingdom), 1% yeast extract (Oxoid), 2% D-glucose], or YNB medium [0.69% yeast nitrogen base without amino acids (Formedium, Norfolk, United Kingdom), 2% D-glucose, 2%
supplemented with amino acids or nucleobases as appropriate for plasmid selection (Ausubel et al., 2007). The filamentous fungi were routinely maintained and grown on potato dextrose agar or broth [PDA (Oxoid) or PDB (Sigma-Aldrich)] except A. fumigatus which was on Aspergillus complete medium (ACM) (Paolletti et al., 2005) and B. cinerea, on Vogel's medium (Vogel, 1964) Where necessary, media were solidified with 2% agar (Sigma-Aldrich, St. Louis, MO, United States).

Chemicals

With the exception of hygromycin B (PanReac Applichem), and ziram and thiram (provided by Taminco BVBA), all drugs were from Sigma-Aldrich. Stock solutions of chemicals used in this study were prepared in water, DMSO, HCl or ethanol as solvent (Table 1). Aliquots were added to growth media as required to give the specified final concentrations.

Growth Inhibition and Toxicity Assays

Yeast growth inhibition assays were performed with broth cultures in 48-well microtitre plates, with continuous shaking at 30°C in a BioTek Powerwave XS microplate spectrophotometer, as described previously (Moreno-Martinez et al., 2015). P. aeruginosa was tested in a similar way but with growth in 96-well plates (Greiner Bio-one; Stonehouse, United Kingdom), in LB broth and at 37°C. Spores of A. fumigatus were inoculated from ACM plates to ACM broth (15,000 spores ml⁻¹). Aliquots (150 µl) of the spore suspension plus any chemical supplements, as specified, were transferred to 96-well plates and cultured statically over 48 h at 37°C, with OD₆₀₀ measured daily in a BioTek EL800 microplate spectrophotometer. B. cinerea (10,000 spores ml⁻¹) and Z. tritici (20,000 spores ml⁻¹) and R. solani (1 mg ml⁻¹ of mycelium) were prepared as above in Vogel's or PDB media, respectively, and cultured over several days at 24°C, 120 rev. min⁻¹. Human cells (TE671, rhabdomyosarcoma RD cell line) were cultured in DMEM (Sigma) supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 100 U ml⁻¹ penicillin, 100 µg ml⁻¹ streptomycin, in 25 cm² cell culture flasks, 36.5°C, 5% oxygen. Toxicity to the TE671 cells was assayed using the CCK-8 reagent (Sigma) as described previously (Moreno-Martinez et al., 2015). To assess plant toxicity, the compounds were sprayed onto the surface area of lettuce leaves and the average surface of resultant lesions was measured after 3 days using ImageJ.

For assaying antifungal combinations, concentrations of agents used were those determined from preliminary assays to be just sub-inhibitory or slightly inhibitory when supplied individually. For yeast, growth (OD₆₀₀) was monitored every 30 min over at least 18 h. Exponential-phase growth rates were calculated and expressed as percentage inhibition relative to control growth in the absence of added inhibitors.

For filamentous fungi, culture densities (OD₆₀₀) determined after 48 h (A. fumigatus) or 4–7 days (plant pathogens) were also expressed in terms of percentage inhibition relative to control growth.

Screen hits were considered as those compounds showing a percentage inhibition when in combination that was greater by 20% than the sum of inhibitory effects observed when the compounds were supplied individually.

Checkerboard Assays

All culturing and preparation for checkerboard assays adhered to EUCAST guidelines (Rodriguez-Tudela et al., 2008; Arendrup et al., 2012), with the exception that media and cell concentrations were the same as for the growth inhibition assays to ease comparison. Briefly, culture aliquots were transferred to 96-well microtitre plates with chemicals added as specified. The inoculated plates were incubated statically for 24 h (S. cerevisiae and C. albicans), 48 h (C. neoforms and A. fumigatus) or 4–7 days (plant pathogens) under either ambient air conditions or anaerobic conditions [10% CO₂, 10% H₂, and 80% N₂] in a Whitley DG250 Anaerobic Workstation (Don Whitley Scientific). OD₆₀₀ was then measured with a BioTek EL800 microplate spectrophotometer. Fractional inhibitory concentration (FIC) as an indicator of synergy was calculated as described (Hsieh et al., 1993). To test whether combinations were fungicidal or fungistatic, 4 µl of cell suspension (S. cerevisiae) treated as above were transferred to YPD agar and incubated for 24 h at 30°C to determine colony forming ability.

Biofilm Inhibition Assays

Biofilm metabolic activity was measured by the XTT (tetrazolium salt, 2,3-bis-[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) (Sigma) reduction assay (Zago et al., 2015). Single yeast colonies were used to inoculate YPD broth cultures in Erlenmeyer flasks and incubated at 37°C with orbital shaking at 120 rev. min⁻¹ overnight. Cultures were diluted to OD₆₀₀~0.01 in RPMI 1640 medium and 100 µl aliquots transferred to 96-well microtitre plates (Greiner Bio-One; Stonehouse, United Kingdom) before static incubation for 2 h. Non-adherent cells were removed by three gentle washes with PBS, then 100 µl of fresh RPMI 1640 were added to each well. Plates were incubated at 37°C with orbital shaking at 100 rev. min⁻¹ for 24 h. After biofilm formation, biofilms were washed and drugs were added as specified. Cultures were incubated for a further 24 h. The wells were washed three times with PBS and the XTT reaction was performed in YNB by adding XTT to 210 µg ml⁻¹ and menadione to 4.2 µM. After 3 h, 100 µl of the reaction solution was transferred to a new 96-well plate and the absorbance at 490 nm was measured using a BioTek EL800 microplate spectrophotometer.

Assay of Quinine Uptake

Quinine uptake was assayed by measuring quinine absorbance at 350 nm as described previously (Tindall et al., 2018). Briefly, overnight cultures were diluted to OD₆₀₀~0.5 in fresh YPD medium and cultured for a further 4 h with shaking. Quinine hydrochloride was added in combination with sodium bicarbonate, hygromycin B or no drug and cells incubated for 20 min at 30°C, 120 rev. min⁻¹. Cells were harvested, washed, resuspended in 10% (w/v) perchloric acid – 2 M sodium methanesulfonate, and then lysed using acid-washed beads. Supernatant was collected after centrifugation (16,000g, 5 min) and A₃₅₀ measured with an Ultrospec 2000 UV/visible
spectrophotometer (Amersham Pharmacia Biotech; Amersham, United Kingdom).

**Mistranslation Assays**

For quantitative determination of mistranslation, *S. cerevisiae* was transformed with a dual luciferase reporter plasmid encoding firefly and *Renilla* luciferases separated by a UAA stop codon (Keeling et al., 2004) and cultured in YNB broth supplemented appropriately for plasmid selection. Cultures were diluted to OD$_{600}$~0.5 in YPD and 300 µl aliquots transferred to 48-well microtiter plates with compounds added as specified. Plates were incubated at 30°C for 4 h with shaking. Cell extracts were prepared and luciferase activities were measured as described previously (Moreno-Martinez et al., 2015).

**RESULTS**

**Discovery of Novel, Synergistic Antifungal Combinations**

Following recent work suggesting translation fidelity to be a new target for combinatorial treatment of undesirable fungi (Moreno-Martinez et al., 2015), we hypothesized that alternative groups of compounds which compromise the availability of functional amino acids for protein synthesis (Figure 1) could offer novel antifungal combinations against this target. As fungal demand for particular amino acids can be satisfied by exogenous supply (e.g., from mammalian serum), which could undermine targeting of amino acid availability, we reasoned that methionine and tryptophan availability could be good candidates in human pathogens; serum levels of these amino acids are low (Tagliamonte et al., 1973; Motil et al., 1994). Furthermore, as cysteine is not an essential amino acid, there is decreased risk that agents targeting cysteine exert toxicity in humans. Therefore, we focused on inhibitors targeting aromatic and sulfur-containing amino acids. Besides sulfate transport inhibitors (chromate, molybdate, orthovanadate, oxalate, malonate, probenecid, bicarbonate, and selenate), which provoke cysteine and methionine starvation (Markovich, 2001; Holland et al., 2010; Moreno-Martinez et al., 2015), we examined amino acid transport inhibitors [quinine and eugenol inhibit aromatic amino acid uptake (Khozoie et al., 2009; Darvishi et al., 2013; Tindall et al., 2018)], amino acid biosynthesis inhibitors [cyprodinil inhibits methionine synthesis (Masner et al., 1994; FRAC, 2018)], non-proteinogenic amino acids [L-DOPA, DL-ethionine, norvaline compete with proteinogenic amino acids (Hartman et al., 2007)], and agents that modify thiol containing amino acids [thiram, ziram, mancozeb (Santos et al., 2009; Dias et al., 2010; Roede and Jones, 2014) and copper; copper additionally targets FeS biosynthesis required for synthesis of certain amino acids (Alhebshi et al., 2012; Vallieres et al., 2017)]. These agents were tested in combination with either: (i) another agent that impairs availability of functional amino acids, or (ii) an aminoglycoside solution.
antibiotic. Agents were used at concentrations determined in preliminary experiments to be just subinhibitory (or barely inhibitory) when supplied individually. This design demanded relatively high concentrations of some agents (see section "Discussion"); however, the added volume never exceeded 3% of the final volume (Table 1).

Combination screens were performed against three plant pathogens (ascomycetes B. cinerea and Z. tritici, and the basidiomycete R. solani) and three human pathogens (ascomycetes C. albicans and A. fumigatus, and the basidiomycete C. neoformans). Screen hits were determined as compounds giving a percentage inhibition in combination that was greater by 20% than the sum of inhibitory effects of the compounds when supplied individually, adapted from Foucquier and Guedj (2015). Among the 172 combinations tested, at least one agent from each of the classes targeting different pathways (Figure 1) produced synergistic-type inhibition when combined with at least one other agent (Figure 2A). Twenty-three of these combinations showed significant inhibition against more than one pathogen (Figure 2B). Among these 23, five combinations comprised a sulfate transport inhibitor and an aminoglycoside, with the chromate + hygromycin combination exhibiting synergistic-type inhibition of four of the test fungi. These included A. fumigatus, previously shown to resist synergy from chromate with the alternative aminoglycoside paromomycin (Moreno-Martinez et al., 2015).

### TABLE 1 | Compound concentrations used in this study.

| Compounds                      | Solvent | R. solani | B. cinerea | S. tritici | A. fumigatus | C. neoformans | C. albicans | P. aeruginosa | Human TE671 |
|--------------------------------|---------|-----------|------------|------------|--------------|---------------|--------------|---------------|-------------|
| Sodium chromate                | Water   | 10 µM     | 10 µM      | 10 µM      | 75 µM        | 12.5 µM       | 25 µM        | ND            | ND          |
| Sodium molybdate               | Water   | 1 mM      | 1 mM       | 1 mM       | 30 mM        | 1 mM          | 10 mM        | ND            | ND          |
| Sodium orthovanadate           | Water   | 200 µM    | 2 mM       | 250 µM     | 15 mM        | 1 mM          | 250 µM       | 3 mM          | 40 µM       |
| Sodium oxalate                 | Water   | 5 mM      | 5 mM       | 25 µM      | 3 mM         | 5 mM          | 5 mM         | ND            | ND          |
| Sodium malonate dibasic        | Water   | 20 mM     | 20 mM      | 10 mM      | 30 mM        | 30 mM         | 30 mM        | ND            | ND          |
| Probenecid                     | DMSO    | 10 µM     | 10 µM      | 10 µM      | 1.5 mM       | 1 mM          | 1 mM         | ND            | ND          |
| Sodium bicarbonate             | Water   | 1.25 mM   | 20 mM      | 500 µM     | 30 mM        | 10 mM         | 25 mM        | 30 mM         | 30 mM       |
| Sodium selenate                | Water   | 500 µM    | 500 nM     | 100 µM     | 100 µM       | 50 µM         | 30 mM        | 30 mM         | 75 µM       |
| Thiram technical               | DMSO    | 10 ng/ml  | 5 ng/ml    | 10 ng/ml   | 750 ng/ml    | 100 ng/ml     | 500 ng/ml    | ND            | ND          |
| Ziram technical                | DMSO    | 50 ng/ml  | 1 ng/ml    | 25 ng/ml   | 750 ng/ml    | 100 ng/ml     | 500 ng/ml    | 3 µg/ml       | 25 ng/ml    |
| Mancozeb                       | DMSO    | 75 ng/ml  | 50 ng/ml   | 100 ng/ml  | 5 µg/ml      | 100 ng/ml     | 750 ng/ml    | ND            | ND          |
| Quinine hydrochloride dihydrate| 70% EtOH| 1 mM      | 1 mM       | 500 µM     | 2 mM         | 250 µM        | 2.5 mM       | 2.5 mM        | 75 µM       |
| Eugenol                        | 70% EtOH| 100 µM    | 100 µM     | 100 µM     | 1 mM         | 125 µM        | 600 µM       | 3 mM          | 500 µM      |
| Copper(II) sulfate pentahydrate| Water   | 75 µM    | 1 mM       | 75 µM      | 750 µM       | 5 mM          | 5 mM         | 1.5 mM        | ND          |
| Cyprodinil                     | 70% EtOH| 10 µM     | 1 mM       | 200 nM     | 40 µM        | 25 µM         | 50 µM        | 2 mM          | 750 nM      |
| 3,4-Dihydroxy-L-phenylalanine   | 1 M HCl | 425 µM    | 1 mM       | 425 µM     | 1 mM         | 1 mM          | 5 mM         | ND            | ND          |
| DL-Ethionine                   | 1 M HCl | 10 µM     | 200 nM     | 500 µM     | 500 µM       | 1 mM          | 5 mM         | ND            | ND          |
| DL-Norvaline                   | Water   | 15 mM     | 15 mM      | 20 mM      | 20 mM        | 20 mM         | 20 mM        | 20 mM         | 20 mM       |
| Streptomycin sulfate salt      | Water   | 15 mg/ml  | 5 mg/ml    | 1 µg/ml    | 10 mg/ml     | 500 µg/ml     | 35 mg/ml     | ND            | ND          |
| Paromomycin sulfate salt       | Water   | 25 µg/ml  | 50 µg/ml   | 500 ng/ml  | 10 mg/ml     | 12.5 µg/ml    | 200 µg/ml    | 50 µg/ml      | 1 mg/ml     |
| Hygromycin B                   | Water   | 250 mg/ml | 500 mg/ml  | 250 mg/ml  | 15 µg/ml     | 625 ng/ml     | 10 µg/ml     | 40 µg/ml      | 50 µg/ml    |
| Quinacrine dihydrochloride     | Water   | ND        | 100 µM     | ND         | ND           | ND            | ND           | 200 µM        | ND          |
| Mefloquine hydrochloride       | 70% EtOH| ND        | ND         | ND         | ND           | ND            | ND           | 1 mM          | ND          |
| Primaquine bisphosphate        | Water   | ND        | 100 µM     | ND         | ND           | ND            | ND           | ND            | ND          |

Concentrations listed (except those in red) were selected as the highest concentrations of the individual compounds which allowed growth of the indicated microorganisms, or metabolic activity of TE671 cells, at a rate that did not differ significantly from the control rate. In red, maximum concentrations that could be used while ensuring either that the added volume from stock solution was ≤3% of final volume, or to preclude inhibition by HCl solvent; these concentrations may be lower than just-subinhibitory.
FIGURE 2 | Drug interactions among 172 combinations of agents assayed against six pathogenic fungi. (A) For assaying antifungal combinations, fungi were incubated in the presence of just sub-inhibitory or barely inhibitory concentrations of agents supplied individually or in the indicated combinations (the concentrations used are listed and explained in Table 1). Growth was measured as described in the section “Materials and Methods.” Combinations showing a >20 percentage-point greater effect of the combination versus the sum of the drugs’ individual % effects were considered screen hits and are represented in pink in the grid (lighter pink = stronger synergistic-type interaction). Compounds are color-coded; each color represents a class described in Figure 1. (B) Synergistic-like combinations common to different fungi, with the green scale indicating the numbers of the test species affected. (C) Synergistic-like combinations common to the different human pathogens or the different plant pathogens.
as was confirmed here. Six of the 23 combinations that were effective cross-species involved a tryptophan transport inhibitor (quinine or eugenol) and an aminoglycoside (Figure 2A). These combinations did not work against Z. tritici and only six of the 172 combinations gave inhibition of this phytopathogen, whereas ≥12 combinations were effective against each of the other tested species. No combination appeared to act synergistically against all three plant pathogens (Figure 2C). On the other hand, ziram + hygromycin, like chromate + hygromycin, inhibited all three human pathogens. Generally, combinations involving a dithiocarbamate (ziram or thiram) and an aminoglycoside seemed to target specifically fungal pathogens of humans, and encompassed 3 of the 23 combinations (Figure 2). Of those 23, nine did not include an aminoglycoside antibiotic: these were quinine combined with three different sulfate transport inhibitors, orthovanadate + cyprodinil, selenate + norvaline, and a dithiocarbamate with either copper, molybdate, or norvaline (Figure 2). The dithiocarbamate + copper combination is used in agriculture. Synergistic-type inhibition by bicarbonate + quinine was observed in four of the six test fungi and so had one of the broadest spectra. This combination conferred very strong growth inhibition, with ∼100% reduction of C. albicans growth yield at quinine and bicarbonate concentrations which individually had little effect (Figure 3).

Checkerboard analysis was performed against all six pathogens to corroborate synergies for some of the key combinations observed from the screen (Supplementary Table S2). Most of the combinations of interest detected from the screen were shown to be synergistic (only 2 exceptions out of 17), with the lowest FIC index values being 0.06 for chromate + hygromycin against C. albicans and 0.19 for paromomycin + eugenol (B. cinerea) as well as quinine + hygromycin (R. solani, B. cinerea). Whereas there were 2 exceptions among hits from the screen, 4 of the checkerboard outcomes indicated synergies that were not detected in the screen, suggesting the screen could be conservative. Three of the outcomes from checkerboards that did not match screen results were for C. neoformans, which grew poorly in the static cultures used for the checkerboard assay.

The results revealed a number of combinations that produced synergistic growth inhibition of the fungi. Some of the most effective combinations were tested in the bacterium P. aeruginosa and in a human cell line. However, no evidence for synergy was found, suggesting that the synergies may be fungi-specific (Supplementary Figure S1 and Supplementary Table S1).
also tested key combinations against the yeast *S. cerevisiae*, to enable this model’s use for insights to mode of action (below). With the exception of orthovanadate + cyprodinil, the main combinations that produced synergistic-type inhibition against more than two fungal pathogens also did so against *S. cerevisiae*, albeit less markedly in the case of ziram + hygromycin (Supplementary Figure S2). Regarding combinations of an aromatic amino acid transport inhibitor with an aminoglycoside, the data suggested a stronger synergistic effect of quinine + hygromycin than eugenol + paromomycin on *S. cerevisiae*.

**Synergies Involving Quinoline-Containing Drugs Have Fungicidal and Anti-biofilm Actions**

Several of the most effective combinations in the above screens involved quinine, with quinine + hygromycin and quinine + bicarbonate appearing especially effective cross-species (Figure 2A). The antimalarial quinine is a food and drug approved agent, like hygromycin and bicarbonate, so these novel combinations provided a good focus for further investigation. Resistance erodes the efficacy of current antifungal drugs, but resistance is typically less common against fungicidal than fungistatic drugs (Anderson, 2005). To determine whether the combinations with quinine were fungicidal or fungistatic, we set up checkerboard growth assays with the drugs followed by transfer to drug-free control medium to assess retention of colony forming ability, using the yeast model. The data revealed that both of the quinine combinations, with either bicarbonate or hygromycin, were fungicidal: cells exhibiting growth inhibition during incubation in the presence of compounds were unable to form colonies when recovered to the control medium (Figure 4A).

*Candida albicans* was among the pathogens synergistically inhibited by the quinine + bicarbonate/hygromycin...
combinations. This organism’s ability to form drug-resistant biofilms has been associated with high mortality rates in infected, immunocompromised patients (Silva et al., 2017; Van Dijck et al., 2018). We tested the effect of both of the new combinations against fungal metabolic activity within biofilms. In both cases, biofilm metabolic activity was decreased by >60% with the combinations, at doses of each agent which had no effect individually (Figure 4B). Therefore, the synergy was effective against C. albicans within biofilms.

Quinine is one of several quinoline-derived antimalarial drugs. We hypothesized that antifungal synergy with bicarbonate or hygromycin may not be restricted to quinine, so tested different examples of these agents for synergistic interactions against representative plant and human pathogens (B. cinerea and C. albicans). In both organisms, quinacrine gave strong synergistic-type inhibition in combination with bicarbonate, but not hygromycin. Primaquine and mefloquine exhibited synergy with both compounds, particularly bicarbonate (Figure 5). Quinoline-derived compounds are used in medicine, but not yet in agriculture and plant toxicity might be an issue. Therefore, we tested for effects of the agents on leaf material, from lettuce. The compounds were sprayed at different concentrations onto leaves and the average surface area of any arising lesions determined. Treating the leaves with quinine or quinacrine, at the concentrations used above against the plant pathogen (i.e., 1 mM quinine and 100 µM quinacrine), produced negligible damage (lesions) (Figure 6A). The subtoxicity concentrations in planta of bicarbonate and hygromycin were also determined (not shown), according to doses that produced <10% surface-area lesions; these concentrations were respectively, 5 and 50 times higher than the subinhibitory concentrations used against B. cinerea. We tested whether quinacrine + bicarbonate (the most effective combination against B. cinerea) had a synergistic effect on plant material, at the same concentrations used against B. cinerea. No leaf lesions were observed (Figure 6B). In conjunction with the data for bacterial and human cells (Supplementary Figure S1 and Supplementary Table S1), the data indicated that synergistic inhibition by the combinations involving quinoline-derived compounds was selective for fungi.

Mechanisms of Synergistic Action
The hypothesized mode of action of the combinations was perturbation of mRNA translation fidelity, via amino acid depletion. The principal mode(s) of quinine drug action is unresolved, but one effect detected first in the yeast model is that quinine competes with tryptophan to cause tryptophan starvation (Khozoie et al., 2009; Tindall et al., 2018). To test a role for tryptophan here, we used a S. cerevisiae trp1Δ mutant defective for tryptophan biosynthesis, so reliant on uptake of the amino acid from the growth medium. We reasoned that this strain should be hyper-sensitive to a synergistic action which involves tryptophan starvation. As observed previously (Khozoie et al., 2009; Tindall et al., 2018), the auxotrophic trp1Δ mutant was sensitive to quinine alone (only a small sensitization was observable at the quinine concentration used here) (Figures 7A,B). However, trp1Δ cells were no more sensitive to the quinine + bicarbonate combination, relative to
Quinine alone, than the wild type (Figures 7A,C). In contrast, the
trp1Δ mutant was hyper-sensitive to the quinine + hygromycin
combination (Figures 7B,C). This suggested that tryptophan
depletion in conjunction with quinine exposure exacerbates the
action of hygromycin specifically.

Cellular quinine levels were assayed to determine whether
bicarbonate or hygromycin may alter drug uptake, an alternative
potential explanation for the synergies. Hygromycin did not
have a significant effect on quinine uptake. In contrast, cells
incubated with bicarbonate showed ~3-fold greater quinine
uptake (Figure 8A). Bicarbonate additions can make media more
alkaline (the media used here were unbuffered) and we observed
in a previous study that NaOH had a stimulatory effect on quinine
uptake (Tindall et al., 2018). The bicarbonate concentration used
in the combination treatments (7.5 mM) increases the pH of YPD
medium from 6.25 to ~6.5 (Figure 8B), which is sufficient to
explain some exacerbation of growth inhibition by quinine: an
increase of ~0.36 pH units increased quinine-dependent growth
inhibition from ~25% to >55% relative to control growth at the
same pH values (Figure 8C). The results show that stimulation
of growth-inhibitory quinine action by bicarbonate is correlated
with increased quinine uptake, and may be related to medium
alkalinization by bicarbonate.

To test whether synergistic growth inhibition was reflected by
synergistic mistranslation, we used a quantitative mistranslation
assay. The assay tests for inappropriate readthrough of a
UAA stop codon, positioned between ORFs encoding Renilla
and firefly luciferases. The firefly luciferase should only be
expressed following UAA readthrough, so the ratio of the
luciferase activities reflects the rate of mistranslation. The
quinine + bicarbonate combination did not increase the rate of
stop codon readthrough (Figure 9A). However, readthrough was
increased ~4-fold by a combination of quinine + hygromycin,
where neither agent alone had a strong effect at the doses used
(Figure 9B).

Quinoline-containing compounds are known to provoke
reactive oxygen species (ROS) production (Radfar et al., 2008;
Tafazoli and O’Brien, 2009; Lalave et al., 2016). As ROS may
in turn promote oxidation of RNA or of proteins involved in
translation (Ling and Soll, 2010; Vallieres and Avery, 2017b),
alternative potential causes of mistranslation, we tested whether
the synergy between quinine + hygromycin (associated with
elevated mistranslation) could be suppressed by the absence of
oxygen. However, synergy was slightly enhanced rather than
rescued under anaerobic growth conditions (Figure 9C). The
absence of rescue by anaerobicity leaves open the starting
hypothesis: that amino acid limitation by quinine (rather than
ROS generation) could be the relevant mechanism exacerbating
mistranslation caused by hygromycin. In contrast, we showed
that bicarbonate enhanced quinine uptake (and resultant growth
inhibition), without stimulating stop codon readthrough. The
data indicate that the different combinations involving quinine
could exert different modes of synergistic antifungal action.

**DISCUSSION**

Previously, it was reported that combination of a sulfate transport
inhibitor with an aminoglycoside synergistically inhibits growth
of several fungi (Moreno-Martinez et al., 2015). The present
results establish that diverse compounds which can alter amino
acid availability in different ways, exert synergistic antifungal
inhibition when combined with other agents impairing amino
acid availability or with aminoglycosides. Despite these common
features of the agents tested, the mechanism of synergistic
action is not the same for every combination. Moreover, the
dataset greatly expands this repertoire of synergistic interactions
affecting fungal pathogens of both plants and humans.

Amino acid biosynthesis has been described as an important
target of antifungal agents (Jastrzebowska and Gabriel, 2015).
Numerous studies have shown that auxotrophic mutants of
fungi pathogenic to humans, impaired in biosynthesis of
particular amino acids, exhibit growth defects or at least reduced
virulence in vivo. Furthermore, chemicals targeting amino acid
biosynthetic enzymes can exert good antifungal activity in vitro
(Jastrzebowska and Gabriel, 2015). Inhibitors of such fungal
enzymes had little if any toxicity in mammalian systems and were
not subject to fungal multidrug resistance. Depletion of particular

**FIGURE 6** Quinine and quinacrine show little toxicity in planta. Agents were sprayed onto lettuce leaves which were examined after 3 days for lesions arising from quinine or quinacrine individually (A), and quinacrine in combination with bicarbonate (B). The images in panel (A) correspond to the relevant, indicated drug concentrations. Total surface area of the leaf disks was 2 cm². The values are means ± SEM from eight leaves. Ctrl, control; QNR, 100 µM quinacrine; Bic, 20 mM bicarbonate.
amino acids within cells can alter the competition between cognate and non-cognate aminoacyl-tRNAs, leading to mRNA mistranslation (Gallant and Lindsley, 1998; Farabaugh and Bjork, 1999; Sorensen, 2001). Perturbation of translation fidelity may be a particularly attractive antifungal action as it not only causes loss of (essential) protein functions, but also gain of toxic function through formation of inhibitory protein aggregates (Holland et al., 2007). Aminoglycosides are thought to promote translation errors by causing a structural alteration in the small ribosomal subunit decoding center, allowing entry of near-cognate tRNAs (Carter et al., 2000; Fan-Minogue and Bedwell, 2008). In the case of combinations with aminoglycosides [e.g., aminoglycoside combined with a sulfate- (Moreno-Martinez et al., 2015) or tryptophan- (this study) transport inhibitor], synergistic growth effects were accompanied by synergistic increases in translation error-rate. This could be explained by the dual targeting of translation fidelity, through different mechanisms, by each agent in the combinations. The absence of synergy against bacteria, a human cell line or plant leaves, reported here, could arise if the effect of at least one agent in a combination is fungus specific. For instance, methionine or cysteine supply in human cells is from the diet and not biosynthesis requiring sulfate uptake. Therefore, sulfate-mimetics (or indeed many other inhibitors of amino acid biosynthesis) should not provoke mistranslation as in fungi (Holland et al., 2010).

A decreased risk of resistance evolution against synergistic combinations of agents should be especially marked when agents have fungicidal rather than fungistatic effects (Anderson, 2005;
that cysteine or tryptophan limitation can mimic the effects (Holland et al., 2010; Tindall et al., 2018). We have also shown media, e.g., cysteine and tryptophan (Khozoie et al., 2009; pertinent to this study, high availability of amino acids in medium components (Hughes and Poole, 1991) or, particularly or fungicide formulations, e.g., by complexation of agents with activities of different inhibitors compared with human serum and that synergies persist at considerably lower concentrations than we selected. Furthermore, rich fungal media can dampen and that synergies against C. albicans combination with either bicarbonate or hygromycin, the efficacy of these synergies against C. albicans biofilms, and that all three compounds are food and drug approved, meaning they could be re-purposed more readily than novel agents due to the low development risk. One limitation could relate to the apparent drug concentrations needed to control fungal growth, as addressed in the next paragraph. One pertinent point concerning quinine is that common quinine analogs, albeit typically more expensive than quinine, can have much lower effective MICs against fungi (Table 1; Vallieres and Avery, 2017b).

Our experimental design, to supply drugs at concentrations which individually were just subinhibitory, demanded concentrations of some agents which were higher than could be realistic for therapeutic use in humans or for large scale crop treatments. However, it should be borne in mind that the design was intended to give the most sensitive detection for discovering synergistic interactions, rather than replicate in vivo systems, and that synergies persist at considerably lower concentrations than we selected. Furthermore, rich fungal media can dampen activities of different inhibitors compared with human serum or fungicide formulations, e.g., by complexation of agents with medium components (Hughes and Poole, 1991) or, particularly pertinent to this study, high availability of amino acids in media, e.g., cysteine and tryptophan (Khozoie et al., 2009; Holland et al., 2010; Tindall et al., 2018). We have also shown that cysteine or tryptophan limitation can mimic the effects of synergistic drug combinations with aminoglycosides, for example (Supplementary Figure S3). Furthermore, we showed that medium pH can markedly influence quinine toxicity. The high-bicarbonate, high-pH nature of DMEM used for human cell culture could explain the relative quinine-susceptibility apparent in TE671 cells, for example (Table 1). Finally, as discussed further below, the present data provide proof of principle for novel synergistic interactions which provide a basis for rational formulation of more effective combinations, if needed, centered around similar chemistries.

We had hypothesized that tryptophan starvation arising from competition between quinine and tryptophan for uptake (Khozoie et al., 2009; Tindall et al., 2018) would stimulate mistranslation in combinations of quinine with bicarbonate (sulfate mimetic) or hygromycin (aminoglycoside). The hypersensitivity to synergistic inhibition by quinine + hygromycin that we observed in a trp1Δ yeast mutant supported this, as did synergistic stimulation of mistranslation by this drug combination. In contrast, our observation that bicarbonate increased quinine uptake could alone account for that synergy as increased intracellular quinine should increase quinine toxicity. The alkalinizing effect of bicarbonate could impact quinine uptake though altered membrane energetics, for example. Moreover, collectively the data indicate that some but not all of the synergies observed here may be underpinned by translation-error, the starting hypothesis which originally informed our choice of agent-classes to test. Certainly several of the test agents will, like bicarbonate, have effects on cells additional to perturbation of translation fidelity. Given that, it will be interesting to resolve mechanism for a broader range of the new synergistic combinations discovered here.

The novel combinations of this study could open opportunities for control of fungal pathogens. The list of

---

**FIGURE 8** Bicarbonate increases quinine uptake. (A) Wild type yeast cells were incubated for 20 min with 4 mM quinine in combination or not with 7.5 mM bicarbonate (Bic) or 10 µg/ml hygromycin (Hyg) [20 min is the approximate mid-point of quinine accumulation by yeast; (Tindall et al., 2018)]. Quinine determinations in cell lysates according to A_{550} were normalized for cell concentration measured just before lysis, with subtraction of background determinations for cells incubated without quinine. ***p < 0.001 according to multiple comparisons (Tukey’s test) by two way ANOVA. The values are means ± SEM from three independent experiments. (B) The pH of YPD medium was determined following additions of different amounts of sodium bicarbonate to give the indicated final concentrations. (C) Wild type yeast was incubated in the presence or absence of 3 mM quinine in YPD medium adjusted to different pH values by NaOH addition. Growth (OD_{600}) was measured after 9 h. The values are means ± SEM from three independent experiments.
agents screened within each class was not exhaustive, so the most promising combinations (e.g., quinine + bicarbonate and quinine + hygromycin) could be used as a basis for computational chemistry and other rational approaches to further optimize properties and synergies. In addition, while we focused primarily on agents targeting sulfur-containing amino acids and aromatic amino acids, it is likely that agents affecting availability of other amino acids may also produce synergies. For example, inhibitors of the NADP- and NAD-glutamate dehydrogenases are known to be active against fungi such as Aspergillus niger and C. albicans (Choudhury et al., 2008; Joshi et al., 2013) and could provide one group of promising candidates for additional synergistic effects.

None of the combinations were synergistic against all six of the fungal pathogens tested. The overall pattern of susceptibility to the different combinations did not map clearly to phylogenetic relatedness of the fungi. For example, whereas 23 combinations strongly inhibited more than one fungus, none were effective against both of the basidiomycetes (R. solani and C. neoformans). Also, with certain exceptions, there was no consistent relationship within the human or plant pathogens. Drug resistance phenotypes can arise from a resistant (or absent) molecular target, reduced drug uptake, increased efflux, or drug inactivation, modification or sequestration. In addition, resistance of certain fungi to certain drugs was so high (e.g., C. albicans with streptomycin) that just-subinhibitory concentrations were not attained for some synergy assays. It is possible that synergy may become detectable at higher concentrations in such cases. The different test-fungi are cultivated on different media, where contents of amino acids, sulfate and other relevant substrates differ, potentially impacting the phenotypes reported here. Previously, it was reported that B. cinerea was not susceptible to synergistic inhibition by chromate + paromomycin (Moreno-Martinez et al., 2015). However, in the present study, several alternative sulfate mimetics (oxalate, bicarbonate, and selenate) did synergistically inhibit B. cinerea when combined with aminoglycosides. This

**FIGURE 9** Quinine synergistically increases mistranslation rate when combined with hygromycin but not bicarbonate. (A,B) S. cerevisiae transformed with a dual-luciferase plasmid encoding the Renilla and firefly luciferases separated by a UAA stop codon was exposed to 3 mM quinine (QN), 7.5 mM bicarbonate (Bic), or 2.5 µg/ml hygromycin (Hyg) alone or in combination for 4 h, before determination of the two luciferase activities. **∗∗∗∗ p < 0.0001** according to multiple comparisons (Tukey’s test) by two way ANOVA. The values are means ± SEM from three independent experiments. (C) Checkerboard assays according to EUCAST procedure, performed in YPD broth with S. cerevisiae BY4743 at the indicated concentrations of quinine and hygromycin in aerobic and anaerobic conditions. The growth values are percentages of growth (OD$_{600}$) with the agents relative to the minus-drug control.
emphasizes the need, where possible, to assess a range of agents associated with a similar mode of action.

CONCLUSION
In conclusion this work unveils a panel of novel chemical combinations, of agents affecting amino acid availability or translation, which synergistically inhibit fungal pathogens. Besides the therapeutic potential for exploitation of these new insights, some of these activities could provide valuable tools for understanding the control of translation fidelity in fungi, and how it may unravel.

DATA AVAILABILITY
Most of the relevant data are included within the manuscript and Supplementary Files. Any additional raw data supporting the conclusions will be made available by the authors on request, without undue reservation, to any qualified researcher.

REFERENCES
Alhebshi, A., Sideri, T. C., Holland, S. L., and Avery, S. V. (2012). The essential iron-sulfur protein Rli1 is an important target accounting for inhibition of cell growth by reactive oxygen species. Mol. Biol. Cell 23, 3582–3590. doi: 10.1091/mbc.E12-05-0413
Anderson, J. B. (2005). Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 3, 547–556. doi: 10.1038/nrmicro1176
Andrenrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., Hope, W., and Eucaast, A. (2012). EUCAT technical note on the EUCAT definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAT-AFST). Clin. Microbiol. Infect. 18, E246–E247. doi: 10.1111/j.1469-0691.2012.03880.x
Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., and Struhl, K. (2007). Current Protocols in Molecular Biology. New York, NY: John Wiley and Sons.
Brent, K. J., and Hollomon, D. W. (2007). Fungicide Resistance In Crop Pathogens: How Can It Be Managed? Brussels: Fungicide Resistance Action Committee.
Brown, G.D., Denning, D.W., Gow, N.A., Levitz, S.M., Netea, M.G., and White, B. T., and Ramakrishnan, V. (2000). Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407, 340–348. doi: 10.1038/35030019
Choudhury, R., Noor, S., Varadarajan, L. P., and Punekar, N. S. (2008). Delineation of an in vivo inhibitor for Aspergillus glutamate dehydrogenase. Enzyme Microb. Technol. 42, 151–159. doi: 10.1016/j.enzmictec.2007.08.011
Cools, H. J., and Hammond-Kosack, K. E. (2013). Exploitation of genomics in fungicide research: current status and future perspectives. Mol. Plant Pathol. 14, 197–210. doi: 10.1111/mpp.12001
Coste, A. T., and Vandenputte, P. (2015). Antifungals: From Genomics to Resistance and the Development of Novel Agents. Norfolk: Caister Academic Press.
Darvishi, E., Omid, M., Bushehri, A. A., Golshani, A., and Smith, M. L. (2013). The antifungal eugenol perturbs dual aromatic and branched-chain amino acid permeases in the cytoplasmic membrane of yeast. PLoS One 8:e76028. doi: 10.1371/journal.pone.0076028
Delarze, E., and Sanglard, D. (2015). Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. Drug Resist. Updat. 23, 12–19. doi: 10.1016/j.drup.2015.10.001
Denning, D. W., and Bromley, M. J. (2015). Infectious disease. How to bolster the antifungal pipeline. Science 347, 1414–1416. doi: 10.1126/science.aaa6097
Dias, P. J., Teixeira, M. C., Telo, J. P., and Sa-Correia, I. (2010). Insights into the mechanisms of toxicity and tolerance to the agricultural fungicide mancozeb in yeast, as suggested by a chemogenomic approach. OMICS 14, 211–227. doi: 10.1089/omi.2009.0134
Fan-Mingh, H., and Bedwell, D. M. (2008). Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity. RNA 14, 118–157. doi: 10.1080/10611280701790334
Fouququier, J., and Guedj, M. (2015). Analysis of drug combinations: current methodological landscape. Pharmacol. Res. Perspect. 3:e00149. doi: 10.1002/prp2.149
FRAC (2018). FRAC Classification on Mode of Action. Available at: http://www.frac.info/docs/default-source/publications/frac-mode-of-action-poster/frac-moa-poster-2018.pdf?sfvrsn=e5694b9a_3
Gallant, J. A., and Lindsley, D. (1998). Ribosomes can slide over and beyond hungry codons, resuming protein chain elongation many nucleotides downstream. Proc. Natl. Acad. Sci. U.S.A. 95, 13771–13776. doi: 10.1073/pnas.95.23.13771
Hartman, M. C., Josephson, K., Lin, C. W., and Szostak, J. W. (2007). An expanded set of amino acid analogs for the ribosomal translation of unnatural peptides. PLoS One 2:e972. doi: 10.1371/journal.pone.0000972
Hill, J. A., O’Meara, T. R., and Cowen, L. E. (2015). Fitness trade-offs associated with the evolution of resistance to antifungal drug combinations. Cell Rep. 10, 809–819. doi: 10.1016/j.celrep.2015.01.009
Holland, S., Lodwig, E., Sideri, T., Reader, T., Clarke, I., Gkargkas, K., et al. (2007). Application of the comprehensive set of heterozygous yeast deletion mutants of an in vivo inhibitor for Aspergillus glutamate dehydrogenase. Enzyme Microb. Technol. 42, 151–159. doi: 10.1016/j.enzmictec.2007.08.011
Hsieh, M. H., Yu, C. M., Yu, V. L., and Chow, J. W. (1993). Synergy assessed by checkerboard. A critical analysis. Diagn. Microbiol. Infect. Dis. 16, 343–349. doi: 10.1016/0732-8893(93)00087-N

AUTHOR CONTRIBUTIONS
SA and CV devised the study and drafted the manuscript. CV and RR performed the experiments. SA and MD provided resources and intellectual input which supported the study.

FUNDING
This work was supported by the Biotechnology and Biological Sciences Research Council (grant numbers BB/N017129/1, BB/P02369X/1).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2018.02355/full#supplementary-material
Hughes, M. N., and Poole, R. K. (1991). Metal speciation and microbial growth - the hard (and soft) facts. *J. Gen. Microbiol.* 137, 725–734. doi: 10.1099/00221287-137-4-725

Islahudin, F., Khoozie, C., Bates, S., Ting, K. N., Pleass, R. J., and Avery, S. V. (2013). Cell wall perturbation sensitizes fungi to the antimalarial drug chloroquine. *Antimicrob. Agents Chemother.* 57, 3889–3896. doi: 10.1128/AAC.00478-13

Jastrzebowska, K., and Gabriel, I. (2015). Inhibitors of amino acids biosynthesis as antifungal agents. *Amino Acids* 47, 227–249. doi: 10.1007/s00726-014-1873-1

Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., and Rex, J. H. (2004). Combination antifungal therapy. *Antimicrob. Agents Chemother.* 48, 693–715. doi: 10.1128/AAC.48.3.693-715.2004

Joshi, C. V., Pathan, E. K., Punekar, N. S., Tupe, S. G., Kapadnis, B. P., and Deshpande, M. V. (2013). A biochemical correlate of dimorphism in a zygomycete *Bisniangium potrasi*: characterization of purified NAD-dependent glutamate dehydrogenase, a target for antifungal agents. *Antonie van Leeuwenhoek* 104, 25–36. doi: 10.1007/s10482-013-9921-5

Keeling, K. M., Lanier, J., Du, M., Salas-Marco, J., Gao, L., Kaenjak-Angeletti, A., Masner, P., Muster, P., and Schmid, J. (1994). Possible methionine biosynthesis in *Benjaminiella poitrasii* in a zygomycete. *Antimicrob. Agents Chemother.* 38, 151–157. doi: 10.1128/AAC.38.1.151-157.1994

Mattu, S. N., Barchiesi, F., Bille, J., Papoutsakis, E. T., and Chryssanthou, E. (2014). Dynamics of proteome oxidative damage across the erythrocytic cycle of resistant *Plasmodium falciparum*. *Free Radic. Biol. Med.* 44, 2034–2042. doi: 10.1016/j.freeradbiomed.2008.03.010

Robbins, N., Spitzer, M., Yu, T., Ceroné, R. P., Averette, A. K., Bahn, Y. S., et al. (2015). An antifungal combination matrix identifies a rich pool of adjuvant molecules that enhance drug activity against diverse fungal pathogens. *Cell Rep.* 13, 1481–1492. doi: 10.1016/j.celrep.2015.10.018

Rodriguez-Tudela, J. L., Arendrup, M. C., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., et al. (2008). EUCAST definitive document EDef 7.1: the method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. *Clin. Microbiol. Infect.* 14, 398–405. doi: 10.1111/j.1469-0691.2007.01935.x

Roede, J. R., and Jones, D. P. (2014). Thiol-reactivity of the fungicide maneb. *Redox Biol.* 2, 651–655. doi: 10.1016/j.redox.2014.04.007

Santos, P. M., Simoes, T., and Sa-Correia, I. (2009). Insights into yeast adaptive response to the agricultural fungicide mancozeb: a toxicoproteomics approach. *Protomics* 9, 657–670. doi: 10.1002/pmc.200800452

Silva, S., Rodrigues, C. F., Araujo, D., Rodrigues, M. E., and Henriques, M. (2017). Candida species biofilms’ antifungal resistance. *J. Fungi* 3. 10.3390/jf3020008

Sorensen, M. A. (2001). Charging levels of four tRNA species in *Escherichia coli* rel + and rel- strains during amino acid starvation: a simple model for the effect of ppGpp on translational accuracy. *J. Mol. Biol.* 307, 785–798. doi: 10.1006/jmbi.2001.4525

Spitzer, M., Robbins, N., and Wright, G. D. (2017). Combinatorial strategies for combating invasive fungal infections. *Virulence* 8, 169–185. doi: 10.1080/21530594.2016.1196300

Tafazoli, S., and O’Brien, P. J. (2009). Amodiaquine-induced oxidative stress in a hepatocyte inflammation model. *Toxicology* 256, 101–109. doi: 10.1016/j.tox.2008.11.006

Taglialomonte, A., Biggio, G., Vargiu, L., and Gessa, G. L. (1973). Free tryptophan in serum controls brain tryptophan level and serotonin synthesis. *Life Sci.* 12, 277–287. doi: 10.1016/0022-1287(73)90361-5

Tindall, S. M., Vallieres, C., Lakhani, D. H., Islahudin, F., Ting, K. N., and Avery, S. V. (2018). Heterologous expression of a novel drug transporter from the malaria parasite alters resistance to quinoline antimalarials. *Sci. Rep.* 8. doi: 10.1038/s41598-018-20816-0

Vallieres, C., and Avery, S. V. (2017a). Metal-based combinations that target protein synthesis by fungi. *Adv. Microb. Physiol.* 70, 105–121. doi: 10.1016/bs.amphs.2017.01.001

Vallieres, C., and Avery, S. V. (2017b). The candidate antimalarial drug MMV665909 causes oxygen-dependent mRNA mistranslation and synergizes with quinoline-derived antimalarials. *Antimicrob. Agents Chemother.* 61:e00459-17. doi: 10.1128/AAC.00459-17

Vallieres, C., Holland, S. L., and Avery, S. V. (2017). Mitochondrial ferreroxin determines vulnerability of cells to copper excess. *Cell Chem. Biol.* 24, 1228–1237. doi: 10.1016/j.chembiol.2017.08.005

Van Dijk, P., Sjollema, J., Cammue, B. P. A., Lagrou, K., Berman, J., d’Enfert, C., et al. (2018). Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. *Microb. Cell* 5, 300–326. doi: 10.15698/mic.2018.07.638

Vandeputte, P., Ferrari, S., and Coste, A. T. (2012). Antifungal resistance and new strategies to control fungal infections. *Int. J. Microbiol.* 2012:713687. doi: 10.1155/2012/713687

Vogl, H. J. (1964). Distribution of lysine pathways among fungi - evolutionary implications. *Am. Nat.* 98, 435–446. doi: 10.1086/282338

Zago, C. E., Silva, S., Sanita, P. V., Barbagli, P. A., Dias, C. M., Lordello, V. B., et al. (2012). The antimalarial drug chloroquine mediates specific proteome oxidative damage across the erythrocytic cycle of resistant *Plasmodium falciparum*. *Free Radic. Biol. Med.* 44, 2034–2042. doi: 10.1016/j.freeradbiomed.2008.03.010

Robbins, N., Spitzer, M., Yu, T., Ceroné, R. P., Averette, A. K., Bahn, Y. S., et al. (2015). An antifungal combination matrix identifies a rich pool of adjuvant molecules that enhance drug activity against diverse fungal pathogens. *Cell Rep.* 13, 1481–1492. doi: 10.1016/j.celrep.2015.10.018

Rodriguez-Tudela, J. L., Arendrup, M. C., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., et al. (2008). EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. *Clin. Microbiol. Infect.* 14, 398–405. doi: 10.1111/j.1469-0691.2007.01935.x

Roede, J. R., and Jones, D. P. (2014). Thiol-reactivity of the fungicide maneb. *Redox Biol.* 2, 651–655. doi: 10.1016/j.redox.2014.04.007

Copyright © 2018 Vallières, Raudo, Dickinson and Avery. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.